Toll Free: 1-888-928-9744

Helicobacter pylori Infections - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Helicobacter pylori Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Helicobacter pylori Infections - Pipeline Review, H2 2016', provides an overview of the Helicobacter pylori Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections
- The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects
- The report assesses Helicobacter pylori Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Helicobacter pylori Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Helicobacter pylori Infections Overview 7 Therapeutics Development 8 Pipeline Products for Helicobacter pylori Infections - Overview 8 Pipeline Products for Helicobacter pylori Infections - Comparative Analysis 9 Helicobacter pylori Infections - Therapeutics under Development by Companies 10 Helicobacter pylori Infections - Therapeutics under Investigation by Universities/Institutes 11 Helicobacter pylori Infections - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Helicobacter pylori Infections - Products under Development by Companies 15 Helicobacter pylori Infections - Products under Investigation by Universities/Institutes 16 Helicobacter pylori Infections - Companies Involved in Therapeutics Development 17 Daewoong Pharmaceutical Co., Ltd. 17 Debiopharm International SA 18 EpiVax, Inc. 19 Frost Biologic, Inc. 20 ImevaX GmbH 21 ImmunoBiology Limited 22 Recce Pty Ltd 23 RedHill Biopharma Ltd. 24 Sequella, Inc. 25 Sigmoid Pharma Limited 26 Helicobacter pylori Infections - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 34 Drug Profiles 36 (amoxicillin sodium + omeprazole sodium + rifabutin) - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Debio-1453 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 DWJ-1325 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 FROST-900 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Helicobacter pylori vaccine - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Helicobacter pylori vaccine - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Helicobacter pylori vaccine - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Helicobacter pylori vaccine - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 HPi-1 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 IMX-101 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 RECCE-327 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Small Molecules for Helicobacter Pylori Infections - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 SQ-109 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Helicobacter pylori Infections - Dormant Projects 57 Helicobacter pylori Infections - Product Development Milestones 58 Featured News & Press Releases 58 Apr 18, 2016: RedHill Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection 58 Mar 08, 2016: RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection 59 Mar 01, 2016: RedHill Biopharma Provides Update on RHB-105 60 Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study's Positive Results 61 Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection 62 Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection 63 Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection 64 Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study 64 Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results 65 May 18, 2015: RedHill Biopharma's Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market 67 May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study 68 Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection 69 Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment 70 Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105 71 Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA 72 Appendix 74 Methodology 74 Coverage 74 Secondary Research 74 Primary Research 74 Expert Panel Validation 74 Contact Us 74 Disclaimer 75
List of Tables
Number of Products under Development for Helicobacter pylori Infections, H2 2016 8 Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Helicobacter pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 17 Helicobacter pylori Infections - Pipeline by Debiopharm International SA , H2 2016 18 Helicobacter pylori Infections - Pipeline by EpiVax, Inc., H2 2016 19 Helicobacter pylori Infections - Pipeline by Frost Biologic, Inc., H2 2016 20 Helicobacter pylori Infections - Pipeline by ImevaX GmbH, H2 2016 21 Helicobacter pylori Infections - Pipeline by ImmunoBiology Limited, H2 2016 22 Helicobacter pylori Infections - Pipeline by Recce Pty Ltd, H2 2016 23 Helicobacter pylori Infections - Pipeline by RedHill Biopharma Ltd., H2 2016 24 Helicobacter pylori Infections - Pipeline by Sequella, Inc., H2 2016 25 Helicobacter pylori Infections - Pipeline by Sigmoid Pharma Limited, H2 2016 26 Assessment by Monotherapy Products, H2 2016 27 Assessment by Combination Products, H2 2016 28 Number of Products by Stage and Target, H2 2016 30 Number of Products by Stage and Mechanism of Action, H2 2016 32 Number of Products by Stage and Route of Administration, H2 2016 33 Number of Products by Stage and Molecule Type, H2 2016 35 Helicobacter pylori Infections - Dormant Projects, H2 2016 57



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify